Skip to main content
SpringerLink
Log in

Small Bowel Cancer

  • Chapter
  • First Online:
Surgical Oncology

Abstract

Small bowel cancers comprise a rare group of neoplasms that account for 1–5 % of all gastrointestinal cancers. These cancers include adenocarcinoma, carcinoid, lymphoma, gastrointestinal stromal tumors (GISTs), sarcomas, and other neoplasms. They share a common characteristic, mainly that they all have a poor overall survival (OS) because of the delay in diagnosis. The mainstay of treatment is surgical resection of the primary tumor, but due to the indolent nature of symptoms, many tumors are widespread at the time of presentation. There have been improvements in both invasive and noninvasive diagnostic studies for small bowel cancers. Capsule endoscopy and double-balloon enteroscopy have offered the clinician a complete evaluation of the small intestine not previously available. OS has improved with better chemotherapy for GISTs and lymphoma, but effective chemotherapy for adenocarcinoma remains elusive.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Cancer Society Facts and Figures 2013. Atlanta. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed on 13 May 2014.

  2. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States. Ann Surg 2009;249(1): 63–71.

    Google Scholar 

  3. Speranza G, Doroshow JH, Kummar S. Adenocarcinoma of the small bowel: changes in the landscape? Curr Opin Oncol. 2010;22:387–93.

    Article  PubMed  CAS  Google Scholar 

  4. Cheung DY, Choi MG. Current advances in small bowel tumors. Clin Endosc. 2011;44:13–21.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Anzidei M, Napoli A, Zini C, Kirchin MA, Catalano C, Passariello R. Malignant tumours of the small intestine: a review of histopathology, multidetector CT and MRI aspects. Br J Radiol. 2011;84:677–90.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Agrawal S, McCarron EC, Gibbs JF, Nava HR, Wilding GE, Rajput A. Surgical management and outcome in primary adenocarcinoma of the small bowel. Ann Surg Oncol. 2007;14(8):2263–9.

    Article  PubMed  Google Scholar 

  7. Kopacova M, Rejchrt S, Bures J, Tacheci I. Small Intestinal Tumours. Gastroenterol Res Pract; 2013; 2013: 702536. doi: 10.1155/2013/702536

  8. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well differentiated endocrine tumors. J Clin Oncol. 2008;26(6):963–70.

    Article  PubMed  Google Scholar 

  9. Balon HR, Brown TLY, Goldsmith SJ, Silberstein EB, Krenning EP, Lang O, Dillehay GD, Tarrance J, Johnson M, Stabin MG. The SNM practice guideline for somatostatin receptor scintigraphy with in-111-pentetreotide. Version 2.0. J Nucl Med Technol. 2011;39(4):317–24.

    Article  PubMed  Google Scholar 

  10. Neuroendocrine Tumors. NCCN guidelines Version 2.2014 http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed on 13 May 2014.

  11. Kobara H, Mori H, Kazi R, Fujihara S, Nishiyama N, Ayaki M, Yachida T, Tani J, Miyoshi H, Kamada H, Morishita A, Oryu M, Tsutsui K, Haba R, Masaki T. Indications for endoscopic submucosal dissection for symptomatic benign gastrointestinal subepithelial or carcinoid tumors originating in the submucosa. Mol Clin Oncol. 2013;1:1002–8.

    PubMed  PubMed Central  Google Scholar 

  12. Strosberg JR, Fisher GA, Benson AB, Malin JL, GEPNET consensus panel, Cherepanov D, Broder MS. Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors. Pancreas. 2013;42(3):397–404.

    Article  PubMed  Google Scholar 

  13. Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Caplin M, Ramage JK. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16:885–94.

    Article  PubMed  CAS  Google Scholar 

  14. Oberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2012;23(7):124–30.

    Google Scholar 

  15. Araujo PB, Cheng S, Mete O, Serra S, Morin E, Asa S, Ezzat S. Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. PLoS One. 2013;8(4):e61538. doi:10.1371/journal.pone.0061538.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Gibbs J. Duodenal adenocarcinoma: is total lymph node sampling predictive of outcome? Ann Surg Oncol. 2004;11(4):354–5.

    Article  PubMed  Google Scholar 

  17. Moon YW, Rha SY, Shin SJ, Chang J, Shim HS, Roh JK. Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. J Cancer Res Clin Oncol. 2010;136(3):387–94.

    Article  PubMed  Google Scholar 

  18. Halfdanarson TR, McWillliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg Oncol. 2007;14(8):797–803.

    Google Scholar 

  19. Ojha A. Primary small bowel malignancies: single center results of three decades. J Clin Gastroenterol. 2000;30(3):289–93.

    Article  PubMed  CAS  Google Scholar 

  20. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestines. Acta Oncol. 2010;49(4):474–9.

    Article  PubMed  Google Scholar 

  21. Chung WC, Paik CN, Jung SH. Prognostic factors associated with survival in patients with primary duodenal adenocarcinoma. Korean J Intern Med. 2011;26(1):34–40.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Chaiyasate K. Prognostic factors in primary adenocarcinoma of the small intestine: 13 year single institution experience. World J Surg Oncol. 2008;6(1):12.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Kelsey CR, Nelson JW, Willett CG. Duodenal adenocarcinoma: patterns of failure after resection and role of chemotherapy. Int J Radiat Oncol Biol Phys. 2007;69(5):1436–41.

    Article  PubMed  Google Scholar 

  24. Fishman PN, Pond GR, Moore MJ. Natural history of chemotherapy effectiveness for advanced adenocarcinoma of the small bowel; a retrospective review of 113 cases. Am J Clin Oncol. 2006;29(3):225–31.

    Article  PubMed  CAS  Google Scholar 

  25. Overman MJ, Varadhachary GR, Kopetz S. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009;27(16):2598–603.

    Article  PubMed  CAS  Google Scholar 

  26. Koo DH, Yun SC, Hong YS, Ryu MH, Lee JL, Chang HM, Kang YK, Kim SC, Han DJ, Lee YJ, Kim TW. Adjuvant chemotherapy for small bowel adenocarcinoma after curative surgery. Oncology. 2011;80(3–4):208–13.

    Article  PubMed  CAS  Google Scholar 

  27. North JH, Pack MS. Malignant tumors of the small intestine: a review of 144 cases. Am Surg. 2000;66(1):46–51.

    PubMed  CAS  Google Scholar 

  28. Hong SH, Koh YH, Rho SY, Byun JH, Oh ST, Im KW, Kim EK, Chang SK. Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol. 2009;39(1):54–61.

    Article  PubMed  Google Scholar 

  29. Zaanan A, Costes L, Gauthier M, Malka M, Locher C, Mitry E, Tougeron D, Lecomte T, Gornet JM, Sobhani I, Moulin V, Afchain P, Taieb J, Bonnetain F, Aparicio T. Chemotherapy of advanced small bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol. 2010;21:1786–93.

    Article  PubMed  CAS  Google Scholar 

  30. DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor. ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013;258(3):46–52.

    Article  Google Scholar 

  31. Alassas M, Ong ES, Kane JM, Gibbs J. Duodenal gastrointestinal stromal tumors: a diagnostic and surgical challenge. Ann Surg. 2008;15:SK2.

    Google Scholar 

  32. DeMatteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG, Singer S, Besmer P, Brennan MF, Antonescu CR. Tumor mitotic rate, size, and location independently predict recurrence after resection or primary gastrointestinal stromal tumor. Cancer. 2008;112:608–15.

    Article  PubMed  Google Scholar 

  33. Bautista-Quach MA, Ake CD, Chen M, Wang J. Gastrointestinal lymphomas: morphology, immunophenotype and molecular features. J Gastrointest Oncol. 2012;3(3):209–25.

    PubMed  PubMed Central  Google Scholar 

  34. Compton C, Byrd D, Garcia-Aguilar J, et al. Small Intestine. In: Compton C, Byrd D, Garcia-Aguilar J, Kurtzman S, Olawaiye A, Washington M, editors. AJCC cancer staging atlas. 2nd ed. New York: Springer; 2012. p. 155–67.

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Kaleida Health/Buffalo General Medical Center, State University of New York at Buffalo, 100 High St., Buffalo, 14203, NY, USA

    David Gleason M.D. & Kimberly E. Miller-Hammond M.D.

  2. Department of Surgery, Jersey Shore University Medical Center/Meridian Heath, 1945 State Highway 33, 4 Floor Ackerman, Neptune, 07753, NJ, USA

    John F. Gibbs M.D.

Authors
  1. David Gleason M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kimberly E. Miller-Hammond M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John F. Gibbs M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John F. Gibbs M.D. .

Editor information

Editors and Affiliations

  1. Department of Surgery, LSU Health Sciences Center-Shreveport, Shreveport, Louisiana, USA

    Quyen D. Chu

  2. Department of Surgery, Jersey Shore University Medical Center, Neptune, New Jersey, USA

    John F. Gibbs

  3. John C. McDonald Regional Transplant Center, Willis Knighton Health System, Shreveport, Louisiana, USA

    Gazi B. Zibari

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gleason, D., Miller-Hammond, K.E., Gibbs, J.F. (2015). Small Bowel Cancer. In: Chu, Q., Gibbs, J., Zibari, G. (eds) Surgical Oncology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1423-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1423-4_10

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1422-7

  • Online ISBN: 978-1-4939-1423-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation